Trastuzumab tedavisi alan her2 pozitif metastatik meme kanseri hastalarında başlangıç anındaki vücut kitle indeksinin ortalama yaşam süresi ve progresyona kadar geçen süre üzerindeki etkisi ve diğer prognostik faktörlerle ilişkisi
Özet
Breast cancer is the most frequently diagnosed cancer in women and obesity is a well established risk factor for breast cancer. Recent studies showed that obesity is linked to a worse prognosis for women diagnosed with breast cancer but there is not so much study in Her2 positive metastatic breast cancer patients to evaluate the effect of obesity. The aim of this study is to evaluate the effect of BMI on overall survive and time to progression and association of other prognostic factors in Her2 positive metastatic breast cancer patients who are treated with trastuzumab. Patients and Methods: This retrospective study is carried out on the patients applied to the department of medical oncology in Ankara University Faculty of medicine, in the period 2005-2014. We analyzed 79 patients who are Her 2 positive and metastatic at the time of the diagnosis or whom metastasis is occured at the first year of adjuvan chemotherapy and treated with trastuzumab. Patients were grouped according to baseline BMI as follows: normal (BMI≤ 25) or obese ( BMI> 25). The primary endpoint of this study is to evaluate the differences of overall survive and time to progression about two groups acoording to baseline BMI. Menopausal status, ER-PR status, metastasis area were taken into account. The secondary endpoint of this study is to evaluate the differences of these prognostic factors about two groups acoording to baseline BMI. Results: 79 patients were enrolled into the study. The patients were grouped according to baseline BMI as follows: normal (BMI≤25) and obese (BMI> 25). Within the analysis cohort, 31 women ( % 39.2) were classified with a normal BMI, and 48 women (% 60.8) were classified as obese. There was no significantly differences between two groups acoording to overall survive and time to progression. But when the five year overall survive is calculated; it is found that obese patients have longer 5 year overall survive (p<0.05). There was no association between obesity and other prognostic factors like ER-PR status, metastasis area in two groups except menopausal status. It is found that obese patients were more likely to be postmenopausal(p=0.047) Conclusion: İn Her2 positive metastatic breast cancer patients whoa are treated with trastuzumab; obesity is not associated with overall survive and time to progression. Our study support that trastuzumab effectiveness not affected by obesity. Much larger scale multicentre studies is needed to evaluate the effect of obesity on breast cancer prognosis in metastatic Her2 positive patients.